Equities

Optomed Oyj

Optomed Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)5.23
  • Today's Change0.07 / 1.36%
  • Shares traded29.37k
  • 1 Year change+76.69%
  • Beta2.5313
Data delayed at least 15 minutes, as of Sep 20 2024 14:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Optomed Oyj is a Finland-based medical technology company and a producer of handheld fundus cameras globally. The Group's Parent Company, Optomed Oyj, is responsible for, among other things, the management of the Group as well as finance and accounting functions, human resources, legal affairs and corporate communication. The Group's business is managed through two reportable segments: Devices and Software. The Devices segment develops, commercializes and manufactures easy-to-use and affordable handheld fundus cameras. The Software segment develops and sells screening software for diabetic retinopathy and cancer screening for healthcare organizations. The Optomed Group consists of the parent company Optomed Oyj and four subsidiaries in Finland, China, the USA and Hong Kong.

  • Revenue in EUR (TTM)14.71m
  • Net income in EUR-4.85m
  • Incorporated2004
  • Employees110.00
  • Location
    Optomed OyjYrttipellontie 1OULU 90230FinlandFIN
  • Phone+358 207413380
  • Fax+358 943153388
  • Websitehttps://www.optomed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bioretec Oy4.08m-3.53m53.89m43.00--8.33--13.22-0.1752-0.17520.20240.3180.41041.233.75110,166.80-35.54-66.83-40.92-97.1969.9770.97-86.61-133.494.04--0.0696--32.7819.77-54.02------
Omda AS35.65m7.73m57.14m295.007.3611.484.381.604.354.3520.602.790.5886238.3610.381,434,162.0013.80-4.9218.03-6.3792.8990.2223.45-9.831.142.560.8946--12.3019.83179.30---3.93--
Senzime AB (publ)4.15m-11.49m57.63m52.00--2.43--13.90-1.16-1.160.41522.670.12791.444.39---35.42-35.69-37.96-38.0029.89-20.59-277.04-558.683.61--0.07--154.7761.90-1.09---3.69--
Gentian Diagnostics ASA12.50m-171.60k60.33m58.00--4.4997.374.83-0.1369-0.13699.4310.200.77561.716.792,522,379.00-1.07-10.76-1.21-11.8651.0641.46-1.37-26.994.83--0.047--32.9827.6354.92---4.92--
OssDsign AB10.89m-10.03m62.25m27.00--3.14--5.72-1.40-1.401.432.300.43112.506.802,572,083.00-39.74-37.92-43.39-43.5683.9468.10-92.18-203.065.92-21.650.0114--96.8453.26-31.30---56.16--
Mentice AB24.75m-899.57k64.25m134.00--4.7844.072.60-0.3998-0.399810.955.970.90463.053.282,301,221.00-3.29-7.69-6.32-13.0785.3683.67-3.63-10.001.00--0.0382--25.5411.7490.81---10.83--
Paxman AB (publ)21.06m2.53m99.24m102.0039.387.7223.984.711.501.5012.547.671.312.746.562,624,791.0015.66-5.0820.74-7.7670.2769.3811.99-5.071.9812.730.0838--43.9929.35180.69--6.26--
Optomed Oyj14.71m-4.85m101.29m110.00--3.70--6.89-0.2761-0.27610.85011.400.47621.694.10129,035.10-15.71-12.95-19.11-15.9067.7765.69-32.98-27.842.67--0.1424--3.003.4718.84--7.26--
C Rad AB40.40m4.25m108.50m89.0026.184.3421.412.691.431.4313.578.611.204.903.055,266,839.0012.695.0917.967.0245.1443.1210.614.862.43--0.00580.0040.9217.44375.0510.8933.69--
BioPorto A/S4.54m-6.70m110.59m33.00--7.87--24.39-0.1397-0.13970.09410.2440.27773.239.021,091,290.00-41.06-71.10-51.28-96.5571.1363.38-147.84-239.225.16--0.0517--6.873.5425.81---51.56--
ADDvise Group AB (publ)136.11m12.11m128.49m637.0021.693.806.110.9440.71910.71918.074.100.51427.245.042,474,039.004.583.725.634.7744.8248.958.915.891.363.240.69130.940544.3038.6227.62--30.35--
Genovis AB11.20m1.52m132.75m37.0087.297.2551.8011.850.26350.26351.943.170.4938----3,432,973.006.7118.567.2121.4564.4165.5113.5823.88--697.000.27180.0054.5435.56449.56--47.59--
Nordhealth As41.29m-9.33m142.70m355.00--3.1998.023.46-1.40-1.406.1711.590.4329--6.731,223,696.00-9.78---11.11--85.82---22.59------0.00--18.60--21.96------
Data as of Sep 20 2024. Currency figures normalised to Optomed Oyj's reporting currency: Euro EUR

Institutional shareholders

33.98%Per cent of shares held by top holders
HolderShares% Held
OP Asset Management Ltd.as of 29 Feb 20241.43m7.30%
Sp-Fund Management Co. Ltd.as of 30 Aug 20241.28m6.51%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Aug 2023953.60k4.86%
Aktia Bank Plc (Investment Management)as of 30 Aug 2024696.42k3.55%
Keskin�inen Ty�el�kevakuutusyhti� Eloas of 29 Feb 2024561.92k2.86%
Handelsbanken Fonder ABas of 31 Aug 2024449.11k2.29%
eQ Varainhoito Oyas of 29 Feb 2024386.99k1.97%
Nordea Investment Management ABas of 29 Feb 2024361.13k1.84%
Keskin�inen Vakuutusyhti� Kalevaas of 29 Feb 2024322.04k1.64%
Danske Bank A/S (Investment Management Finland)as of 31 Jul 2024227.09k1.16%
More ▼
Data from 31 Jan 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.